Skip to main content

Table 12 Laboratory parameters before and after treatment in the safety-set

From: Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

 

Critical values

Pretreatment

Posttreatment

  

Nitroxoline

Contols

p-value*

Nitroxoline

Contols

p-value*

Glucose (mg/dl)

< 55, >160

20/227 (8.8%)

12/226 (5.3%)

0.138

12/206 (5.8%)

7/207 (3.4%)

0.242

Creatinine (mg/dl)

> 1.8

1/228 (0.4%)

1/227 (0.4%)

0.998

1/205 (0.5%)

0/207 (0%)

-

Bilirubin (mg/dl)

< 0.1, >2.0

3/226 (1.3%)

1/227 (0.4%)

0.337

2/205 (1.0%)

4/207 (1.9%)

0.426

SGOT –AST (U/l)

< 35, > = 150

224/226 (99.1%)

225/226 (99.6%)

0.570

203/205 (99.0%)

206/207 (99.5%)

0.564

SGPT - ALT (U/l)

< 35, > = 150

222/226 (98.2%)

225/226 (99.6%)

0.212

204/205 (99.5%)

207/207 (100%)

-

gamma-GT (U/l)

< 3, >38

9/227 (4.0%)

10/226 (4.4%)

0.807

9/205 (4.4%)

6/207 (2.9%)

0.412

Sodium (mmol/l)

< 130, >150

8/228 (3.5%)

6/226 (2.7%)

0.603

11/205 (5.4%)

5/207 (2.4%)

0.132

Potassium (mmol/l)

< 3.6, >6.0

22/228 (9.6%)

19/226 (8.4%)

0.628

19/205 (9.3%)

12/206 (5.8%)

0.229

Calcium (mmol/l)

< 8, >11.5

229/229 (100%)

227/227 (100%)

-

206/206 (100%)

206/206 (100%)

-

Hemoglobin (g/dl)

< 10, >17

0/227 (0%)

0/219 (0%)

-

1/201 (0.5%)

2/204 (1.0%)

0.582

Hematocrit (%)

< 32, >47

25/227 (11.0%)

33/220 (15.0%)

0.197

20/201 (10.0%)

33/204 (16.2%)

0.065

Erythrocytes (Mio/ÎĽl)

< 4, >5.1

29/227 (12.8%)

14/220 (6.4%)

0.024

22/201 (10.9%)

26/205 (12.7%)

0.588

Leucocytes (Tsd/ÎĽl)

< 4, >11.3

25/227 (11.0%)

21/220 (9.5%)

0.605

13/200 (6.5%)

16/204 (7.8%)

0.614

Neutrophiles (%)

< 39, >75

22/225 (9.8%)

37/221 (16.7%)

0.031

15/199 (7.5%)

13/203 (6.4%)

0.656

Eosinophiles (%)

< 1, >10

10/223 (4.5%)

19/219 (8.7%)

0.080

11/199 (5.5%)

8/203 (3.9%)

0.399

Basophiles (%)

0, >15

38/222 (17.1%)

47/220 (21.4%)

0.257

29/199 (14.6%)

38/203 (18.7%)

0.266

Lymphocytes (%)

< 10, >50

9/221 (4.1%)

12/220 (5.5%)

0.391

7/198 (3.5%)

11/203 (5.4%)

0.382

Monocytes (%)

< 3, >25

7/223 (3.1%)

14/220 (6.4%)

0.117

9/199 (4.5%)

6/203 (3.0%)

0.410

Retikulocytes (%)

< 0.5, >2

220/224 (98.2%)

212/218 (97.2%)

0.493

198/200 (99.0%)

200/205 (97.6%)

0.227

Thrombocytes (Tsd/ÎĽl)

< 150, >450

11/225 (4.9%)

8/218 (3.7%)

0.529

10/201 (5.0%)

8/204 (3.9%)

0.608

BSR (mm/1 h)

< 5, >11

134/203 (66.0%)

124/202 (61.4%)

0.343

106/179 (59.2%)

114/187 (61.0%)

0.756

BSR (mm/2 h)

> 25

82/202 (40.6%)

88/200 (44.0%)

0.470

44/178 (24.7%)

57/186 (30.6%)

0.207

  1. BSR-blood sedimentation rate.
  2. *comparison of nitroxoline vs. controls, logistic regression with random center effect.